Evidence map›Paper›PMID 34208059›Full record

ArticleVaccines2021

Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery.

David Peterhoff, Stefanie Thalhauser, Jan M Sobczak, Mona O Mohsen, Christoph Voigt, Nicole Seifert, Patrick Neckermann, Alexandra Hauser, Song Ding, Quentin Sattentau and 3 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Targeted escape of SARS-CoV-2Frontiers in immunology · 2022
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

David PeterhoffInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, 93053 Regensburg, Germany.ORCID 0000-0001-5911-6233
Stefanie ThalhauserInstitute of Pharmaceutical Technology, University of Regensburg, 93053 Regensburg, Germany.
Jan M SobczakDepartment for BioMedical Research, University of Bern, 3010 Bern, Switzerland.
Mona O MohsenDepartment for BioMedical Research, University of Bern, 3010 Bern, Switzerland.
Christoph VoigtInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, 93053 Regensburg, Germany.
Nicole SeifertInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, 93053 Regensburg, Germany.ORCID 0000-0002-2191-523X
Patrick NeckermannInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, 93053 Regensburg, Germany.
Alexandra HauserInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, 93053 Regensburg, Germany.ORCID 0000-0002-9738-392X
Song DingEuroVacc Foundation, 1002 Lausanne, Switzerland.
Quentin SattentauSir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.
Martin F BachmannDepartment for BioMedical Research, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0003-4370-2099
Miriam BreunigInstitute of Pharmaceutical Technology, University of Regensburg, 93053 Regensburg, Germany.ORCID 0000-0002-1320-6820
Ralf WagnerInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, 93053 Regensburg, Germany.
Institute of Medical Microbiology and Hygiene · DEUniversity of Bern · CHUniversity Hospital Regensburg · DEUniversity of Regensburg · DEEurovacc Foundation · CHUniversity of Oxford · GB

Funding

FRISBI and GRAL ANR-10-INBS-05-02 and ANR-17-EURE-0003Horizon 2020 681032Medical Research Council G0000635
6 · The paper itself

Abstract

The delivery of HIV-1 envelope (Env) trimer-based immunogens on the surface of nanoparticles holds promise to promote immunogenicity with the aim of inducing a potent, durable and broad neutralizing antibody (bnAb) response. Towards that goal, we examined the covalent conjugation of Env to 100 nm and 200 nm silica nanoparticles (SiNPs) to optimize conjugation density and attachment stability. Env was redesigned to enable site-specific cysteine-mediated covalent conjugation while maintaining its structural integrity and antigenicity. Env was anchored to different sized SiNPs with a calculated spacing of 15 nm between adjacent trimers. Both particle sizes exhibited high in vitro stability over a seven-day period. After attachment, 100 nm particles showed better colloidal stability compared to 200 nm particles. Importantly, the antigenic profile of Env was not impaired by surface attachment, indicating that the quaternary structure was maintained. In vitro Env uptake by dendritic cells was significantly enhanced when Env was delivered on the surface of nanoparticles compared to soluble Env. Furthermore, multivalent Env displayed efficiently activated B cells even at Env concentrations in the low nanomolar range. In mice, antibody responses to nanoparticle-coupled Env were stronger compared to the free protein and had equivalent effects at lower doses and without adjuvant.

Indexed as

EnvHIV vaccinesilica nanoparticlesstabilized envelope trimer

Identifiers

PMID34208059
PMCPMC8230641
OpenAlexW3168555285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.